Nature Reviews Clinical Oncology

Article	Citations
From little subclones grow mighty oaks	1340
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	1303
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	913
Sacituzumab govitecan plus pembrolizumab improves outcomes	904
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	867
A new standard of care for advanced-stage urothelial carcinoma	736
Novel ICI–TKI combination improves HCC outcomes	715
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles	633
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	594
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown	589
Ecological management of the microbiota in patients with cancer	552
Hodgkin lymphoma: great progress with room for improvement	540
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	524
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	510
Gut microbiota in colorectal cancer development and therapy	503
Current understanding and management of CAR T cell-associated toxicities	495
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	436
Ponatinib superior to imatinib in Ph+ ALL	408
Mortality is similar with active monitoring	373
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	352
From ESMO 2022	352
Belzutifan as a new option in pheochromocytomas and paragangliomas	350
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	350
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	342
Sacituzumab tirumotecan improves OS in mTNBC	342

Humanized mouse models for immuno-oncology research	341
Emerging trends in the global burden of colorectal cancer	341
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	334
Understanding and overcoming multidrug resistance in cancer	330
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	314
Biomarkers for immunotherapy of hepatocellular carcinoma	305
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	286
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	283
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	279
Vebreltinib effective in MET-amplified NSCLC	266
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	264
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	264
Improving outcomes in patients with oesophageal cancer	264
Spatial landscapes of cancers: insights and opportunities	231
MicroRNAs in oncology: a translational perspective in the era of AI	227
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	218
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	216
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	206
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	206
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	202
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	196
Women with clinically node negative breast cancer can safely avoid axillary surgery	184
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	182
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	182
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	177
Prospective comparisons support the use of navigational bronchoscopy	171
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	155
DREAMseq of therapy for BRAF-mutant melanoma	154
From ESMO 2023: advances in lung cancer	153
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA	149
Targeting chromosomal instability in patients with cancer	149
Synergistic integration of regional and systemic therapies in uveal melanoma	144
Circulating tumour DNA — looking beyond the blood	142
Mitigating acute chemotherapy-associated adverse events in patients with cancer	138
Long-term outcomes following CAR T cell therapy: what we know so far	132
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	132
Multiomics STEP up in correlative analysis of response to CAR T cells	130
From the ESMO Congress 2023	129
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	127
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	126
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	124
Sentinel lymph node biopsy improves surgical management of cervical cancer	121
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	120
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	117
Author Correction: Innovative approaches for lung cancer screening and interception	115
Lung cancer in patients who have never smoked — an emerging disease	114
Newly approved cancer drugs in China — innovation and clinical benefit	111
Clinical implications of T cell exhaustion for cancer immunotherapy	110
Enhancing immunotherapy with tumour-responsive nanomaterials	110
Targeted biopsy reduces detection of clinically insignificant cancer	110

Claudin 18.2 as a novel therapeutic target	110
T-DXd effective as second-line therapy in G/GEJ cancers	108
Second-line tarlatamab improves OS in SCLC	106
Less-frequent surveillance is noninferior to annual mammography	105
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	103
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC	103
Translating biological insights into improved management of endometrial cancer	98
Patient value over patent value: the mandate for open-source oncology	94
Barriers in access to oncology drugs — a global crisis	90
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology	89
Two decades of advances in clinical oncology — lessons learned and future directions	87
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics	85
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	82
BrECADD raises the bar in classical Hodgkin lymphoma	81
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	81
HSCT prolongs remission of high-risk CTCLs	80
Thermal ablation is safer than resection of colorectal liver lesions	77
Promising OS with oncolytic virotherapy	77
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	74
GPRC5D-CAR T cells active in MM	71
Promise with co-administration of CAR T cells	70
Efficacy of TILs confirmed	67
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	66
Cured but breathless: the growing burden of DIILD in cancer survivors	64
Non-financial conflicts of interest	64
Nirogacestat effective in desmoid tumours	64
Multidisciplinary management of meningiomas in the era of precision oncology	61
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	61
Engineering platelets as cancer therapeutics	59
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	58
Exploiting bacteria for cancer immunotherapy	52
The current state of the art and future trends in RAS-targeted cancer therapies	51
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	51
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management	47
Repotrectinib effective in ROS1-fusion-positive NSCLC	46
KN046 shows tolerability and activity in TNBC	46
Problematic crossovers in cancer drug trials	45
Neoadjuvant pembrolizumab improves outcomes	44
Clinical implementation of multi-cancer early detection tests: can we find a path forward?	44
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	42
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	42
Realizing the benefits of tumour-agnostic access requires a national health learning system	41
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	41
The emerging roles of γδ T cells in cancer immunotherapy	38
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	38
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	36
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	36
The changing landscape of oncology clinical trials in Latin America	35
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours	34
CAR T cells induce durable remission of neuroblastoma	33
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons	33
National value-based pricing negotiation for oncology drugs — lessons from China	33
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	33
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	33
GPRC5D as a novel immunotherapeutic target in multiple myeloma	33
Personalizing adjuvant therapy for patients with colorectal cancer	32
Epcoritamab is active in large B cell lymphomas	31
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	29
Menin–KMT2A interaction inhibitor shows promise	28
Laparoscopic hemihepatectomy is safe and effective	28
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer	28
Adjuvant chemotherapy improves OS in UTUC	26
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma	25
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC	24
Systemic induction therapy and the expanding frontier of bladder preservation in MIBC	24
The microbiota in radiotherapy-induced cancer immunosurveillance	23
The age of foundation models	22
Laparoscopic TME is non-inferior	21
Synthetic lethal strategies for the development of cancer therapeutics	20
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	20
Platinum-ineligible: atezolizumab preferable	19
HER2-targeted therapies beyond breast cancer — an update	19
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?	19
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia	19
Early promising results with the novel KRASG12C inhibitor divarasib	18
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients	17
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?	17
Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma	17
Will I feel better? Raising the bar for quality of life in oncology	16
Precision oncology for KRASG12C-mutant colorectal cancer	15

Getting the right combination to break the epigenetic code	15
Cancer mRNA vaccines: clinical advances and future opportunities	15
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	14
The next generation of immunotherapies for lung cancers	13
Docetaxel-based CRT improves survival in cisplatin-ineligible patients	13
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations	13
T-DXd is effective after T-DM1	12
Engaging results with glofitamab in DLBCL	12
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data	12
Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells	12
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer	11
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions	11
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	11
Thermal immuno-nanomedicine in cancer	10
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck	10
A new era for glioma therapy — targeting mutant IDH	9
Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma	9
A new first-line option for advanced-stage anal squamous cell carcinoma	9
From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer	9
Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care	9
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer	9
Electronic cigarettes, smoking and lung cancer risk: some evidence about the continuum of harm	9
HER2-directed therapy improves urothelial cancer outcomes	9
Dabrafenib–trametinib moves to the first line in low-grade glioma	9
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	8
Is NETTER-2 a practice-changing trial?	8
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	8
In what clinical settings are the MASAI trial results applicable?	7
Molecular tumour boards — current and future considerations for precision oncology	7
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	7
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer	7
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	7
Towards biomarker-driven therapies for urothelial carcinoma	7
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer	7
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	7
The molecular blueprint of targeted radionuclide therapy	7
Targeting cuproplasia and cuproptosis in cancer	6
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3	6
Perioperative therapy effective in high-risk HCC	6
SUNLIGHT illuminates the activity of bevacizumab	6
Synergy of EphB2 and PD-1 blockade	6
The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma	6
Cultivating the microbiome to enhance cancer immunotherapy	6
Asciminib is safe and effective in patients with newly diagnosed CML	5
Neoantigen vaccines at the crossroads: lessons from AMPLIFY-201	5
Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?	5
Criteria for the translation of radiomics into clinically useful tests	5
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	5
Circulating tumour cells for early detection of clinically relevant cancer	5
Combination neoadjuvant chemotherapy improves outcomes	5
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes	5
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC	5
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions	5
Adjuvant S-1 extends OS in biliary tract cancers	5
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL	5
Blinatumomab improves outcomes in infant ALL	5
Transanal TME noninferior to the laparoscopic approach	5
Targeting the glioblastoma resection margin with locoregional nanotechnologies	5
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer	5
Towards equitable AI in oncology	4
Does OptiTROP-Lung05 open a new frontier for first-line ADC–ICI combinations in NSCLC?	4
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach	4
Envisioning trans-inclusive and trans-specific cancer care	4
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?	4
The SONIA trial shows the power and challenges of academic research	4
AI accurately identifies targetable alterations in lung cancer histological images	4
Leptomeningeal metastatic disease: new frontiers and future directions	4
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer	4
Novel assessment of epigenetic imprinting biomarkers for the diagnosis of thyroid nodules	4
Early promising results with addition of an ICI and an anti-angiogenic to TACE	4
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	4
RECITE this mantra in chemotherapy-induced thrombocytopenia: treat patients, not platelets	4
Novel combination delivers prolonged OS	4
From WCC 2022	4
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects	3
The development of CAR T cells for patients with CNS malignancies	3
Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC	3
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches	3
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders	3
NIR-II light in clinical oncology: opportunities and challenges	3
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy	3
Computational immunogenomic approaches to predict response to cancer immunotherapies	3
The global epidemiology of acute myeloid leukaemia	3
cfDNA screening for fetal aneuploidy facilitates maternal cancer detection	3
Bemarituzumab enters the FIGHT	3
Progress in systemic therapy for advanced-stage urothelial carcinoma	3
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’	3
CAR T cells show superiority over standard therapies for RRMM	3
The global burden of lung cancer: current status and future trends	3
Pharmacological reactivation of p53 in the era of precision anticancer medicine	3
Neoadjuvant GOLP is effective in high-risk intrahepatic cholangiocarcinoma	3
THOR provides new data on the efficacy of erdafitinib	3
Therapeutic targeting of mismatch repair-deficient cancers	3
From ASCO 2023	3
Optimizing CAR T cell therapy for solid tumours: a clinical perspective	3